Skip to main content
Evidence Snapshot

Cytochrome P450 2J2

CHEMBL3491 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:04:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3491
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cytochrome P450 2J2 as ChEMBL target CHEMBL3491, mapped to UniProt P51589. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cytochrome P450 2J2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3491
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P51589
Cytochrome P450 2J2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cytochrome P450 2J2 matters

As of 2026-09-13

Cytochrome P450 2J2 is reviewed as Cytochrome P450 2J2 (UniProt P51589); the current evidence base includes 24 approved drugs, 156 compounds, and 77 assays, with lead potency reaching pChEMBL 7.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 24 approved drugs, 156 compounds, and 77 assays for this target. The dominant activity type is IC50. CHEMBL1479 is the current potency anchor at pChEMBL 7.9.

Use CHEMBL1479 as the tractability anchor when discussing potency (pChEMBL 7.9).

Activity source · ChEMBL 36 via Core Engine
24 approved pChEMBL 7.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cytochrome P450 2J2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P51589, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

156
Total Compounds
77
Total Assays
24
Approved Drugs
IC50: 120.0, KI: 7.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1479
 7.9 IC50 Approved
No preferred name
CHEMBL1479
 7.7 Ki Approved
No preferred name
CHEMBL1017
 7.0 Ki Approved
No preferred name
CHEMBL30008
 7.0 Ki Clinical
No preferred name
CHEMBL208528
 6.8 Ki —

Approved Drugs

Structure Compound First Approval
TELMISARTAN
CHEMBL1017
 1998
AMODIAQUINE
CHEMBL682
 1982
DANAZOL
CHEMBL1479
 1976
MICONAZOLE
CHEMBL91
 1974
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:04:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3491